Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells

Journal of Neurochemistry

Volumn 126, Issue 2, 2013, Pages 223-233

  Arsenault, Jason ^a   Ferrari, Enrico ^a,b   Niranjan, Dhevahi ^a   Cuijpers, Sabine A G ^a   Gu, Chunjing ^a   Vallis, Yvonne ^a   O'Brien, John ^a   Davletov, Bazbek ^a,c  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF LINCOLN   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

botulinum; growth factor; neuroendocrine tumor; neuropeptide; SNAP25; targeting

Indexed keywords

BOTULINUM TOXIN A; CILIARY NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; DERMORPHINE; DYNORPHIN 17; EPIDERMAL GROWTH FACTOR; NEUROPEPTIDE; SOMATOSTATIN; SUBSTANCE P; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; DRUG TRANSPORT; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IMMUNOCYTOCHEMISTRY; INHIBITION KINETICS; INSULINOMA; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NEUROSECRETORY CELL; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT;

BOTULINUM; GROWTH FACTOR; NEUROENDOCRINE TUMOR; NEUROPEPTIDE; SNAP25; TARGETING;

ANIMALS; BOTULINUM TOXINS, TYPE A; CELL LINE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEUROBLASTOMA; NEURONS; NEUROPEPTIDES; NOREPINEPHRINE; POTASSIUM CHLORIDE; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT FUSION PROTEINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TRITIUM;

EID: 84879939934     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12284     Document Type: Article

References (63)

1. Amiche M., Delfour A., and, Nicolas P., (1988) Structural requirements for dermorphin opioid receptor binding. Int. J. Pept. Protein Res. 32, 28-34.
2. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., and, Caleo M., (2008) Long-distance retrograde effects of botulinum neurotoxin A. J. Neurosci. 28, 3689-3696.
3. Arsenault J., Cabana J., Fillion D., Leduc R., Guillemette G., Lavigne P., and, Escher E., (2010) Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism. Biochem. Pharmacol. 80, 990-999.
4. Bajohrs M., Rickman C., Binz T., and, Davletov B., (2004) A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep. 5, 1090-1095.
5. Bajohrs M., Darios F., Peak-Chew S. Y., and, Davletov B., (2005) Promiscuous interaction of SNAP-25 with all plasma membrane syntaxins in a neuroendocrine cell. Biochem. J. 392, 283-289.
6. Bangaru M. L. Y., Woodliff J., Raff H., and, Kansra S., (2010) Growth Suppression of Mouse Pituitary Corticotroph Tumor AtT20 Cells by Curcumin: A Model for Treating Cushing's Disease. PLoS ONE 5, e9893.
7. Batcher E., Madaj P., and, Gianoukakis A. G., (2011) Pancreatic Neuroendocrine Tumors. Endocr. Res. 36, 35-43.
8. Binz T., and, Rummel A., (2009) Cell entry strategy of clostridial neurotoxins. J. Neurochem. 109, 1584-1595.
9. Boyd R. S., Duggan M. J., Shone C. C., and, Foster K. A., (1995) The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F. J. Biol. Chem. 270, 18216-18218.
10. Chaddock J. A., and, Marks P. M., (2006) Clostridial neurotoxins: structure-function led design of new therapeutics. Cell. Mol. Life Sci. 63, 540-551.
11. Chaddock J. A., Purkiss J. R., Duggan M. J., Quinn C. P., Shone C. C., and, Foster K. A., (2000a) A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18, 147-155.
12. Chaddock J. A., Purkiss J. R., Friis L. M., Broadbridge J. D., Duggan M. J., Fooks S. J., Shone C. C., Quinn C. P., and, Foster K. A., (2000b) Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. 68, 2587-2593.
13. Chaddock J. A., Purkiss J. R., Alexander F. C., et al,. (2004) Retargeted clostridial endopeptidases: inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord. 19 (Suppl 8), S42-S47.
14. Chen S., and, Barbieri J. T., (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl Acad. Sci. USA 106, 9180-9184.
15. Cryer P. E., (1992) Pheochromocytoma. West. J. Med. 156, 399-407.
16. Darios F., Niranjan D., Ferrari E., et al,. (2010) SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc. Natl Acad. Sci. USA 107, 18197-18201.
17. Davletov B., Bajohrs M., and, Binz T., (2005) Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins. Trends Neurosci. 28, 446-452.
18. Davletov B., Ferrari E., and, Ushkaryov Y., (2012) Presynaptic neurotoxins: An expanding array of natural and modified molecules. Cell Calcium 52, 234-240.
19. Ekong T. A., Feavers I. M., and, Sesardic D., (1997) Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143 (Pt 10), 3337-3347.
20. Fasshauer D., Sutton R. B., Brunger A. T., and, Jahn R., (1998) Conserved structural features of the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs. Proc. Natl Acad. Sci. USA 95, 15781-15786.
21. Ferolla P., Faggiano A., Mansueto G., et al,. (2008) The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J. Endocrinol. Invest. 31, 277-286.
22. Ferrari E., Maywood E. S., Restani L., Caleo M., Pirazzini M., Rossetto O., Hastings M. H., Niranjan D., Schiavo G., and, Davletov B., (2011) Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity. Toxins (Basel) 3, 345-355.
23. Ferrari E., Soloviev M., Niranjan D., Arsenault J., Gu C., Vallis Y., O'Brien J., and, Davletov B., (2012) Assembly of protein building blocks using a short synthetic Peptide. Bioconjug. Chem. 23, 479-484.
24. Fisher C. E., Sutherland J. A., Krause J. E., Murphy J. R., Leeman S. E., and, vanderSpek J. C., (1996) Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: in vitro destruction of cells bearing substance P receptors. Proc. Natl Acad. Sci. USA 93, 7341-7345.
25. Foster K. A., (2005) A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. Drug Discov. Today 10, 563-569.
26. Foster K., and, Chaddock J., (2010) Targeted secretion inhibitors-innovative protein therapeutics. Toxins (Basel) 2, 2795-2815.
27. Foster K. A., Adams E. J., Durose L., et al,. (2006) Re-engineering the target specificity of Clostridial neurotoxins-a route to novel therapeutics. Neurotox. Res. 9, 101-107.
28. Frankel A. E., Woo J-H., and, Neville D. M,. (2009) Immunotoxins, in Principles of Cancer Biotherapy (, Oldham R. K., and, Dillman R. O,. eds), pp. 407-449. Springer, Netherlands.
29. Gao Y., Zorman S., Gundersen G., Xi Z., Ma L., Sirinakis G., Rothman J. E., and, Zhang Y., (2012) Single reconstituted neuronal SNARE complexes zipper in three distinct stages. Science 337, 1340-1343.
30. Garg A., and, Banitt P. F., (2004) Pheochromocytoma and myocardial infarction. South. Med. J. 97, 981-984.
31. Golden S. H., Robinson K. A., Saldanha I., Anton B., and, Ladenson P. W., (2009) Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab. 94, 1853-1878.
32. Harper C. B., Martin S., Nguyen T. H., et al,. (2011) Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J. Biol. Chem. 286, 35966-35976.
33. Hermann A., Maisel M., Liebau S., Gerlach M., Kleger A., Schwarz J., Kim K. S., Antoniadis G., Lerche H., and, Storch A., (2006) Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. J. Neurochem. 98, 629-640.
34. Kirmani S., (2012) Molecular genetic testing in endocrinology-a practical guide. Endocr. Pract. 18, 85-89.
35. Kroesen M., Lindau D., Hoogerbrugge P., and, Adema G. J., (2012) Immunocombination therapy for high-risk neuroblastoma. Immunotherapy 4, 163-174.
36. Langer M., and, Beck-Sickinger A. G., (2001) Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anticancer Agents 1, 71-93.
37. Langley K., (1994) The neuroendocrine concept today. Ann. N. Y. Acad. Sci. 733, 1-17.
38. Lin P. C., Hsu J. T., Chung C. M., and, Chang S. T., (2007) Pheochromocytoma underlying hypertension, stroke, and dilated cardiomyopathy. Tex. Heart Inst. J. 34, 244-246.
39. Low G., Dhliwayo H., and, Lomas D. J,. (2012) Adrenal neoplasms. Clin. Radiol. 67, 988-1000.
40. Mahrhold S., Rummel A., Bigalke H., Davletov B., and, Binz T., (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014.
41. Martin T. F., and, Grishanin R. N., (2003) PC12 cells as a model for studies of regulated secretion in neuronal and endocrine cells. Methods Cell Biol. 71, 267-286.
42. Meunier F. A., Lisk G., Sesardic D., and, Dolly J. O., (2003) Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 22, 454-466.
43. Middleton R. J., and, Kellam B., (2005) Fluorophore-tagged GPCR ligands. Curr. Opin. Chem. Biol. 9, 517-525.
44. Moyse E., Segura S., Liard O., Mahaut S., and, Mechawar N., (2008) Microenvironmental determinants of adult neural stem cell proliferation and lineage commitment in the healthy and injured central nervous system. Curr. Stem Cell Res. Ther. 3, 163-184.
45. Nichols M. L., Allen B. J., Rogers S. D., et al,. (1999) Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286, 1558-1561.
46. Ossipov M. H., Dussor G. O., and, Porreca F., (2010) Central modulation of pain. J. Clin. Invest. 120, 3779-3787.
47. Pickett A., and, Perrow K., (2011) Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 3, 63-81.
48. Prejbisz A., Lenders J. W., Eisenhofer G., and, Januszewicz A., (2011) Cardiovascular manifestations of phaeochromocytoma. J. Hypertens. 29, 2049-2060.
49. Reynolds B. A., and, Weiss S., (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255, 1707-1710.
50. Richardson P. M., (1994) Ciliary neurotrophic factor: a review. Pharmacol. Ther. 63, 187-198.
51. Schiavo G., Santucci A., Dasgupta B. R., Mehta P. P., Jontes J., Benfenati F., Wilson M. C., and, Montecucco C., (1993) Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335, 99-103.
52. Schiavo G., Matteoli M., and, Montecucco C., (2000) Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766.
53. Shone C. C., and, Melling J., (1992) Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur. J. Biochem. 207, 1009-1016.
54. Sleeman M. W., Anderson K. D., Lambert P. D., Yancopoulos G. D., and, Wiegand S. J., (2000) The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharm. Acta Helv. 74, 265-272.
55. Smith B. A., and, Hecht M. H., (2011) Novel proteins: from fold to function. Curr. Opin. Chem. Biol. 15, 421-426.
56. Somm E., Bonnet N., Martinez A., et al,. (2012) A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J. Clin. Invest. 122, 3295-3306.
57. Südhof T. C., and, Rothman J. E., (2009) Membrane Fusion: Grappling with SNARE and SM Proteins. Science 323, 474-477.
58. Sutton R. B., Fasshauer D., Jahn R., and, Brunger A. T., (1998) Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395, 347-353.
59. Taupenot L,. (2007) Analysis of regulated secretion using PC12 cells. Curr. Protoc. Cell Biol. 15, 1-13.
60. Thirunavukkarasusx N., Ghosal K. J., Kukreja R., Zhou Y., Dombkowski A., Cai S., and, Singh B. R., (2011) Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochem. Biophys. Res. Commun. 405, 684-690.
61. Tritos N. A., and, Biller B. M., (2012) Advances in medical therapies for Cushing's syndrome. Discov. Med. 13, 171-179.
62. Yowler B. C., Kensinger R. D., and, Schengrund C. L., (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 277, 32815-32819.
63. Zhou M., Nakatani E., Gronenberg L. S., Tokimoto T., Wirth M. J., Hruby V. J., Roberts A., Lynch R. M., and, Ghosh I., (2007) Peptide-labeled quantum dots for imaging GPCRs in whole cells and as single molecules. Bioconjug. Chem. 18, 323-332.